Tendonitis Treatment Market By Treatment (Therapy (Hot & Cold Therapy, Physical Therapy, and Shockwave Therapy), Surgical, and Medications (Oral and Topical)), By Application (Achilles Tendonitis, Tennis Elbow, Pitcher’s Elbow, Supraspinatus Tendonitis, and Jumper’s Knee), By End-use (Hospitals, Home Care Settings, Specialty Clinics, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Tendonitis Treatment Market Size is expected to be worth around USD 311.3 billion by 2033 from USD 214.4 billion in 2023, growing at a CAGR of 3.8% during the forecast period 2024 to 2033.

The rising incidence of tendonitis is being driven by several factors, including the growing aging population, increased sports and occupational injuries, and trauma-related physical strain. Adolescents are also experiencing a higher susceptibility to arm, wrist, and hand injuries due to excessive use of electronic devices, raising their risk of developing tendonitis.

The elderly are particularly vulnerable as conditions such as osteoarthritis, rheumatoid arthritis, and osteoporosis make them more prone to tendon-related issues. According to the Bureau of Labor Statistics, over 70,000 Americans with tendonitis miss work annually. In 2021, the World Health Organization estimated that 1.71 billion people worldwide suffer from musculoskeletal conditions, which increase their likelihood of developing tendonitis.

The growing participation in sports and physical activities has led to an increase in sports-related injuries, further contributing to market growth. In fact, sports injuries account for 12% of all hospital-reported injuries in the U.S., many of which involve tendons. A study by sports medicine professors from Duke University and the University of Virginia found that 40 to 50% of competitive runners have experienced Achilles tendinopathy.

Tendonitis cases range between 5 to 10 per 100,000 individuals in the general population, fueling demand for treatment options such as over-the-counter medications, surgeries, and physical therapy. Physical therapy, particularly eccentric strengthening exercises, remains a key treatment for chronic tendon issues, driving further industry expansion.

Key Takeaways

• In 2023, the market for Tendonitis Treatment generated a revenue of USD 214.4 billion, with a CAGR of 3.8%, and is expected to reach USD 311.3 billion by the year 2033.
• The treatment segment is divided into therapy, surgical, and medications, with therapy taking the lead in 2023 with a market share of 47.4%.
• Considering application, the market is divided into Achilles tendonitis, tennis elbow, pitcher’s elbow, supraspinatus tendonitis, and jumper’s knee. Among these, Achilles tendonitis held a significant share of 40.0%.
• Furthermore, concerning the end-use segment, the market is segregated into hospitals, home care settings, specialty clinics, and others. The hospitals sector stands out as the dominant player, holding the largest revenue share of 42.9% in the Tendonitis Treatment market.
• North America led the market by securing a market share of 42.6% in 2023.

Treatment Analysis

The therapy held a significant share of 47.4% due to several factors. Advances in physical therapy techniques, including specialized exercise regimens and manual therapy, are anticipated to drive market expansion. The rising preference for non-invasive treatments over surgical interventions supports this trend, as patients and healthcare providers increasingly seek effective pain management and functional recovery through conservative approaches.

Additionally, the development of advanced therapeutic modalities, such as regenerative medicine techniques including platelet-rich plasma (PRP) and stem cell therapies, contributes to the segment’s growth. Enhanced understanding of tendon healing processes and the integration of personalized therapy plans are projected to further boost demand in this segment. Improved patient outcomes and reduced recovery times associated with these therapies are likely to strengthen their adoption, driving the overall growth of the therapy segment.

Application Analysis

The Achilles tendonitis segment had a tremendous growth rate, with a revenue share of 40.0% owing to various key factors. The increasing incidence of Achilles tendonitis, particularly among athletes and individuals engaged in high-impact sports, drives demand for targeted treatments. The rising awareness of the condition and advancements in diagnostic methods are anticipated to contribute to the segment’s expansion.

Enhanced treatment options, including novel surgical techniques, customized rehabilitation programs, and advanced orthotic devices, are likely to address the specific needs of Achilles tendonitis patients. Additionally, the growing emphasis on preventive care and early intervention strategies supports the segment’s development. As healthcare providers focus on improving outcomes for Achilles tendonitis sufferers, the segment is expected to witness increased adoption of specialized treatments and therapies.

End-use Analysis

The hospitals segment grew at a substantial rate, generating a revenue portion of 42.9% due to several driving factors. Hospitals are expected to remain key players in managing complex tendonitis cases that require advanced diagnostic and treatment capabilities. The increasing prevalence of tendonitis conditions and the demand for comprehensive, multidisciplinary care support the growth of this segment.

Hospitals are likely to benefit from their ability to offer a range of treatment options, including surgical procedures, physical therapy, and post-operative rehabilitation. Additionally, the integration of state-of-the-art medical technologies and the presence of specialized orthopedic and sports medicine departments contribute to the segment’s expansion. As patient populations seek high-quality care and advanced treatment options, hospitals are projected to play a central role in the effective management of tendonitis.

Key Market Segments

By Treatment

• Therapy
  • Hot & Cold Therapy
  • Physical Therapy
  • Shockwave Therapy
• Surgical
• Medications
  • Oral
  • Topical

By Application

• Achilles Tendonitis
• Supraspinatus Tendonitis
• Tennis Elbow
• Pitcher’s Elbow
• Jumper’s Knee

By End-use

• Hospitals
• Specialty Clinics
• Home Care Settings
• Others

Drivers

Growing Occurrence of Sports Injuries

Rising participation in sports and recreational activities has led to an increased frequency of sports-related injuries, including tendonitis. According to the National Safety Council (NSC), approximately 445,642 injuries were caused by exercise equipment in 2022, making it the leading source of sports and recreation-related injuries. This surge in injuries is anticipated to boost demand for effective tendonitis treatments.

Innovative treatments such as SportVis, launched by Pendopharm in May 2021, offer enhanced pain relief for soft tissue injuries, helping individuals return to physical activities more swiftly. The growing use of hyaluronic acid-based treatments, along with the increasing number of sports injuries, is expected to drive the market forward.

Restraints

Lack of Proper Reimbursement Policies

High out-of-pocket costs for advanced tendonitis treatments have impeded market growth, as many patients face financial barriers due to inadequate insurance coverage. The lack of comprehensive reimbursement policies, particularly for innovative therapies like stem cell injections and hyaluronic acid-based treatments, is projected to hamper patient access and adoption.

These financial limitations often prevent patients from seeking timely and effective treatments, potentially worsening their condition. Without adequate policy reform and improved insurance structures, the tendonitis treatment market is likely to experience slower growth, especially in regions with underdeveloped healthcare systems.

Opportunities

Increasing Scope of Treatment

Rising advancements in medical technologies and expanding treatment options are projected to create significant opportunities for market growth. The launch of innovative therapies, such as Boehringer Ingelheim’s RenuTrend in April 2022, which treats tendon and ligament injuries in horses, demonstrates the growing potential of targeted treatments.

As the first injectable therapy of its kind in Europe, it complements existing stem cell treatments, showcasing the expanding range of solutions for tendon-related injuries. This increasing scope of novel and effective treatments for both humans and animals is expected to drive demand, presenting new growth avenues for the tendonitis treatment market.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors exert both positive and negative influences on the tendonitis treatment market. Rising healthcare expenditure in developed economies supports increased access to advanced treatment options, leading to a growing demand for therapies such as corticosteroid injections, physical therapy, and advanced orthopedic solutions.

However, economic downturns and inflationary pressures can limit patient access to these treatments, particularly in low- and middle-income countries. Geopolitical instability and trade disruptions may also impact the supply chain for medical devices and pharmaceuticals, leading to higher costs and delayed access to treatment. On a positive note, government initiatives and healthcare reforms in key regions are likely to improve access to affordable treatments, contributing to the long-term growth of the market.

Latest Trends

Integration of Smart Technology

Increasing integration of smart technology presents a significant trend driving the tendonitis treatment market. Smart prostheses, wearables, and AI-driven diagnostic tools enhance personalized treatment and improve patient outcomes. In September 2022, Ossur launched its revolutionary product, the POWER KNEE, a motor-powered prosthesis equipped with advanced algorithms to detect human movement patterns.

This innovation positively impacts the company’s reputation and offers potential for market expansion by demonstrating the growing role of smart technology in orthopedics. With rising demand for devices that provide real-time feedback and data-driven insights, the market for tendonitis treatment is anticipated to benefit from these cutting-edge developments.

Regional Analysis

North America is leading the Tendonitis Treatment Market

North America dominated the market with the highest revenue share of 42.6% owing to the rising prevalence of sports injuries and an aging population. Increased participation in sports, coupled with a higher awareness of tendon-related conditions, contributed to the growing demand for effective treatments. Technological advancements in treatment options, including non-invasive procedures, also fueled market expansion.

In May 2021, Pendopharm launched SportVis, the only hyaluronic acid treatment approved by Health Canada, which provides effective pain relief for soft tissue injuries, allowing patients to return to their daily activities more quickly. The introduction of such innovative solutions and the growing preference for minimally invasive therapies have further propelled market growth in this region.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

The tendonitis treatment market in the Asia Pacific region is projected to expand significantly during the forecast period, driven by increasing healthcare expenditure and a rising geriatric population. The growing popularity of sports and physical activities in countries like China, Japan, and India has led to a higher incidence of tendon injuries, boosting demand for advanced treatment options.

In December 2021, Delsson, a Singapore-based engineering firm, collaborated with 3D printing experts from Nanyang Technological University (NTU) to develop the X-Brace, a lightweight exoskeleton knee brace nearly 30% lighter than traditional models. This innovation is likely to enhance treatment efficacy and patient mobility, further supporting market expansion in the region.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the Tendonitis Treatment market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the tendonitis treatment market focus on several strategies to drive growth. They invest heavily in research and development to introduce advanced therapies, including biologics and regenerative medicine, aimed at improving patient outcomes.

Strategic collaborations with healthcare providers and expanding product portfolios allow them to reach a broader patient base. Additionally, companies engage in mergers and acquisitions to enhance their market presence and strengthen distribution networks. Targeted marketing efforts and educational programs also help raise awareness about innovative treatment options.

Top Key Players in the Tendonitis Treatment Market

• Zimmer Biomet Holdings, Inc.
• Pfizer
• Stryker
• GlaxoSmithKline PLC
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bayer AG
• AstraZeneca
• Ossur
• Abbott

Recent Developments

• In January 2023: Zimmer Biomet Holdings, Inc. completed the acquisition of Embody, Inc., a company specializing in tendon healing technologies. The acquisition included Embody’s TAPESTRY biointegrative implant and TAPESTRY RC, both designed to promote tendon repair. This acquisition strengthens Zimmer Biomet’s position in the tendonitis treatment market by expanding its offerings with advanced tendon healing solutions, highlighting the growing demand for innovative therapeutic approaches in this space.
• In September 2021: Stryker’s Trauma and Extremities division launched the Citrelock Tendon Fixation Device System. This system featured a unique tendon thread using proprietary resorbable technology, designed to aid in tendon repair. The introduction of this advanced fixation system broadens Stryker’s orthopedic product portfolio and supports the growing need for innovative, less invasive solutions in the tendonitis treatment market.
• In September 2021: Stryker introduced the Citrelock Tendon Fixation Device System, a new product for repairing damaged tendons. The system uses a specialized tendon thread made from citrate, calcium, and phosphate—materials that assist in bone and tendon healing. This product launch represents a critical advancement in the treatment of tendonitis by providing a minimally invasive solution that supports the body’s natural healing processes.
• In July 2021: Ossur launched the Rebound Post-Op Elbow Brace, a non-invasive, lightweight, and adjustable brace designed to optimize the recovery process for patients with severe elbow injuries or those undergoing surgical procedures. This product expanded Ossur’s portfolio and addressed the growing demand for non-surgical, supportive therapies in the tendonitis treatment market.

Report Scope